🔴 Outlook Therapeutics is trading 6.62% down in pre-market after pricing a discounted $55 million share-and-warrant offering

Outlook Therapeutics is trading at $0.83 (-6.62%) in pre-market after pricing a $55 million public offering of shares and warrants at $0.99, creating dilution pressure.

• The August 14 earnings update reported $11.2 million in cash as of June 30 and substantial doubt about continuing as a going concern.
• Approximately $51.1 million in net offering proceeds support a late-2026 launch.
• Broader markets were modestly mixed, making company-specific financing and liquidity concerns the clearer catalyst.